Life Sciences

  • April 02, 2026

    Snell & Wilmer Names Life Sciences Pro As San Diego Leader

    Snell & Wilmer LLP has tapped a longtime corporate attorney who specializes in the life sciences industry to be the new head of its San Diego office.

  • April 02, 2026

    Teva $35M Delayed Generic Inhalers Deal Gets Initial OK

    A Massachusetts federal judge Thursday granted initial approval to a $35 million deal that Teva Pharmaceuticals agreed to pay to resolve claims from a coalition of union healthcare funds that say the company schemed to delay generic competition for its QVAR asthma inhalers.

  • April 02, 2026

    Vape Sellers, Makers Evade Ga. Woman's RICO Scheme Suit

    A Georgia federal judge has tossed a suit against numerous vape sellers and makers alleging they conspired to sell vapes with illegal levels of delta-9 THC, saying her complaint fails to allege any kind of scheme, but rather amounts to describing the normal supply chain.

  • April 01, 2026

    Ex-Wilson Sonsini M&A Co-Head Rejoins Goodwin In SF

    A former partner at Goodwin Procter LLP's Silicon Valley office has rejoined the firm in San Francisco after co-leading Wilson Sonsini Goodrich & Rosati PC's mergers and acquisitions practice for five years, Goodwin announced on Wednesday.

  • April 01, 2026

    7th Circ. Says Ill. BIPA Amendment Applies Retroactively

    The Seventh Circuit held Wednesday that a liability-limiting amendment to Illinois' biometric privacy law applies to every lawsuit pending at the time the amendment took effect, ruling that the amendment is only a procedural change to the law and, therefore, must be applied retroactively.

  • April 01, 2026

    Berkshire Must Defend Trulieve In Worker Death Suit

    An insurance company that is a unit of Berkshire Hathaway had an obligation to defend Trulieve Inc. against a Massachusetts wrongful death lawsuit brought by the family of a cannabis worker, a Florida federal judge has ruled, rejecting arguments that the worker wasn't an employee.

  • April 01, 2026

    3 Federal Circuit Clashes To Watch In April

    The Federal Circuit argument calendar for this month includes Centripetal Networks' appeal of a decision clearing Cisco of infringing cybersecurity patents after a multibillion-dollar award was thrown out, as well as Ecobee's challenge to an $11.5 million infringement verdict involving smart thermostats.

  • April 01, 2026

    DC Cannabis Co. Sues Firm Over Botched Grow Facility

    A cannabis industry-focused engineering firm reneged on a promise to build a fully operational indoor grow facility for a D.C.-based medical dispensary, the company told a D.C. federal court, claiming it is now stuck with the unfinished project and $1 million in specialized equipment that can't be resold.

  • April 01, 2026

    Harvard Researcher Can Get Docs On Prosecution Motives

    A Massachusetts federal judge ruled Wednesday that a Harvard Medical School researcher and Russian national charged with smuggling frog embryo specimens can see emails and other documents regarding the government's decision to prosecute her, citing evidence the case was "vindictive."

  • April 01, 2026

    Astellas Beats $115M Milestone Claim In Del. Chancery Ruling

    A Delaware Court of Chancery judge has ruled that Astellas Pharma Inc. is not obligated to pay up to $115 million in disputed drug development milestone payments tied to its acquisition of Potenza Therapeutics Inc., finding that the clinical trials at issue never met the contract's definition of a Phase II study.

  • April 01, 2026

    Mass. Cannabis Businesses Say Repeal Bid Misleads Voters

    A coalition of Massachusetts cannabis business owners Wednesday challenged the constitutionality of a proposal to repeal retail marijuana legalization at the ballot box this November.

  • April 01, 2026

    PBM Opioid Crisis Suit Stays In Federal Court, Judge Says

    A Michigan federal judge on Tuesday denied a request from the state attorney general to remand to state court a suit accusing two pharmacy benefit managers of fueling the opioid crisis, saying the case will remain in federal court because work performed for federal and nonfederal clients cannot be separated.

  • April 01, 2026

    CFO Scores $867K Win In Health Device Co. Wage Suit

    A wearable health device company must pay its former chief financial officer nearly $867,000 after a Connecticut federal jury determined it stiffed him on his full wages and benefits, according to court filings.

  • March 31, 2026

    Split 4th Circ. Affirms Injunction On W.Va. Drug Discount Law

    A split Fourth Circuit panel sided with a trio of pharmaceutical manufacturers Tuesday that opposed a West Virginia law addressing drug delivery in the 340B program, saying the law attempted to reshape the "contractual bargain" Congress makes with private parties through its spending powers.

  • March 31, 2026

    Novartis Seeks To Block New Wash. 340B Drug-Pricing Law

    Novartis has called on a Washington federal judge to block a new state law it claims illegally expands the subsidies manufacturers must pay under the federal government's 340B Drug Pricing Program, arguing drugmakers will lose millions of dollars annually if the law is allowed to take effect in June.   

  • March 31, 2026

    Novartis Can't Nix FCA Suit Alleging MS Drug Kickbacks

    Novartis must face a False Claims Act suit alleging it improperly had doctors prescribe its multiple sclerosis drug, a New York federal judge said Monday, finding the relator plausibly pled scienter by bringing evidence that the company "kept meticulous track" of how many prescriptions doctors wrote for the drug.

  • March 31, 2026

    Anesthesia Parent Can't Duck Antitrust Suit, But Affiliate Can

    The parent company of U.S. Anesthesia Partners Inc. remains in the crosshairs of a private antitrust suit accusing it of trying to monopolize Texas anesthesia services, while a federal judge dismissed for now claims against an affiliate that he said was too far removed from the alleged rollup strategy.

  • March 31, 2026

    Moderna, Pfizer Want Bayer's COVID-Shot Patent Suits Tossed

    Pharmaceutical giants Moderna and Pfizer-BioNTech have asked a Delaware federal judge to dismiss lawsuits seeking to recover royalties from sales of their respective COVID-19 vaccines, which plaintiff Bayer claims were made possible via infringement of its patent.

  • March 31, 2026

    BioPharma Spoofing Suit Against Canadian Banks Proceeds

    A New York federal judge has ruled that Quantum BioPharma Ltd. can pursue most of its lawsuit accusing the brokerage arms of the Royal Bank of Canada and the Canadian Imperial Bank of Commerce of spoofing the biopharmaceutical company's stock, finding that Quantum plausibly alleged that the scheme occurred and that the banks acted recklessly.

  • March 31, 2026

    Full Fed. Circ. Is Told Panel Defied EcoFactor In DePuy Case

    DePuy Synthes is urging the full Federal Circuit to review a circuit panel's decision reviving patent infringement litigation against it, saying the panel majority undermined the court's en banc EcoFactor decision on when to admit expert testimony.

  • March 31, 2026

    Biogen Paying $5.6B For Apellis As 4 Firms Advise

    Biogen Inc. said Tuesday that it has agreed to acquire Apellis Pharmaceuticals Inc. in a cash transaction valued at about $5.6 billion, with four law firms steering the transaction focused on key therapies for kidney and eye disorders. 

  • March 31, 2026

    Beasley Allen Seeks Stay Of DQ In Federal J&J Talc MDL

    The Beasley Allen Law Firm asked a New Jersey federal court on Monday to hold off on disqualifying it from talc litigation against Johnson & Johnson while it appeals the disqualification order which it called "unprecedented and incorrect."

  • March 31, 2026

    Insurer Says Yale Was 'Misleading' In $4.1M Transplant Claim

    A Liberty Mutual unit accused Yale University's health system of making "serious and material misstatements" about a plan member's bone marrow transplant, the insurer said in its answer and counterclaim for a declaratory judgment that it can continue to deny the $4.1 million claim.

  • March 31, 2026

    Kirkland, Goodwin Steer Lilly $7.8B 'Sleep-Wake' Disorder Deal

    Pharmaceutical giant Eli Lilly & Co., advised by Kirkland & Ellis LLP, announced plans Tuesday to acquire daytime sleepiness-focused pharmaceutical company Centessa Pharmaceuticals PLC, led by Goodwin Procter LLP, in a deal worth up to $7.8 billion.

  • March 31, 2026

    Cancer Vaccine Developer Files Ch. 7 After Trials Fall Short

    A Denmark-based biotechnology firm filed for Chapter 7 liquidation Tuesday in Delaware with more than $10 million in debt after its prospective cancer vaccine failed to measure up under testing and win regulatory approval last year.

Expert Analysis

  • The Next Pressure Point In Digital Health: Informed Consent

    Author Photo

    Two new federal digital health initiatives will usher in a new era where virtual care, software-enabled devices and home-based monitoring are integrated into care and reimbursement models, with the impact of shifting rules and opportunities felt most immediately in the context of informed consent, says Kimberly Chew at Husch Blackwell.

  • Series

    Law School's Missed Lessons: Intentional Career-Building

    Author Photo

    A successful legal career is built through intention: understanding expectations, assessing strengths honestly and proactively seeking opportunities to grow and cultivating relationships that support your development, say Erika Drous and Hillary Mann at Morrison Foerster.

  • Trending At The PTAB: The Policies That Are Redefining IPR

    Author Photo

    The evolution of the Patent Trial and Appeal Board's inter partes review institution regime last year, coupled with the policy considerations behind that evolution, marks a shift toward greater gatekeeping of the U.S. Patent and Trademark Office's resources and patent enforcement rights, say attorneys at Finnegan.

  • 4 Trends Shaping Drug And Medical Device Law For 2026

    Author Photo

    2025 saw some significant legal developments with potential impact for drug and device manufacturers, ranging from growing skepticism in science and regulatory entities to new regulation of artificial intelligence, say attorneys at Faegre Drinker.

  • Trending At The PTAB: The Journey Of IPR Institution In 2025

    Author Photo

    Over the course of 2025, inter partes review institution at the Patent Trial and Appeal Board evolved into a more restrictive, policy-driven regime with reshaped discretionary briefing and assessment, and increasing procedural requirements, say attorneys at Finnegan.

  • A Meaningful Shift In FDA's Biosimilarity Analysis

    Author Photo

    The U.S. Food and Drug Administration's potential pivot away from routinely requiring comparative efficacy studies for interchangeable biosimilar applications would not lower regulatory standards, but instead allow applicants to allocate resources toward establishing more probative evidence, says Theodore Thompson at Stinson.

  • 4 Developments That Defined The 2025 Ethics Landscape

    Author Photo

    The legal profession spent 2025 at the edge of its ethical comfort zone as courts, firms and regulators confronted how fast-moving technologies and new business models collide with long-standing professional duties, signaling that the profession is entering a period of sustained disruption that will continue into 2026, says Hilary Gerzhoy at HWG Law.

  • Navigating AI In The Legal Industry

    Author Photo

    As artificial intelligence becomes an increasingly integral part of legal practice, Law360 guest commentary this year examined evolving ethical obligations, how the plaintiffs bar is using AI to level the playing field against corporate defense teams, and the attendant risks of adoption.

  • How Fractional GCs Can Manage Risks Of Engagement

    Author Photo

    As more organizations eliminate their in-house legal departments in favor of outsourcing legal work, fractional general counsel roles offer practitioners an engaging and flexible way to practice at a high level, but they can also present legal, ethical and operational risks that must be proactively managed, say attorneys at Boies Schiller.

  • 2025 Legal Milestones That Will Shape Psychedelics Sector

    Author Photo

    As 2025 draws to a close, psychedelic drug development stands at an inflection point, experiencing unprecedented momentum through recent sweeping regulatory changes and landmark clinical milestones, amid rapidly evolving regulatory expectations, say Odette Hauke at Odette Alina LLC and Kimberly Chew at Husch Blackwell.

  • Series

    Nature Photography Makes Me A Better Lawyer

    Author Photo

    Nature photography reminds me to focus on what is in front of me and to slow down to achieve success, and, in embracing the value of viewing situations through different lenses, offers skills transferable to the practice of law, says Brian Willett at Saul Ewing.

  • What Defense Teams Must Know About PFAS Testing Methods

    Author Photo

    Whether testing for per- and polyfluoroalkyl substances produces results meaningful for litigation depends on the validity of the sampling methodology — so effectively defending these claims requires understanding the scientific and legal implications of different PFAS testing protocols, say attorneys at Hollingsworth.

  • Series

    Law School's Missed Lessons: Practical Problem Solving

    Author Photo

    Issue-spotting skills are well honed in law school, but practicing attorneys must also identify clients’ problems and true goals, and then be able to provide solutions, says Mary Kate Hogan at Quarles & Brady.

  • Intellectual Property Challenges In AI-Driven Drug Discovery

    Author Photo

    Given the adoption of artificial intelligence-based drug discovery platforms and the U.S. Patent and Trademark Office's recent guidance on determining inventorship in AI-assisted inventions, practitioners must consider unprecedented questions regarding inventorship, patentability standards and infringement liability, says Paul Calvo at Sterne Kessler.

  • Reel Justice: 'The Mastermind' And Juror Decision-Making

    Author Photo

    The recent art heist film “The Mastermind” forces viewers to discern the protagonist’s ambiguous motives and reconcile contradictions, offering lessons for attorneys about how a well-crafted trial narrative can tap into the psychological phenomena underlying juror decision-making, says Veronica Finkelstein at Wilmington University.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.